Hutchison China Meditech Limited Expands Its Collaboration With Innovent Biologics, Inc

  • Hutchison China Meditech Limited (HCM) has expanded its global collaboration agreement with Innovent Biologics, Inc.
  • The collaboration agreement is for evaluating the safety and efficacy of Innovent’s sintilimab injection, Tyvyt® amalgamated with Chi-Med’s surufatinib.
  • The partnership will allow the two companies to jointly explore the potential application of Tyvyt® and surufatinib combination therapy in solid tumors with rising global demand.
  • On 10th October 2019, at the time of writing, GMT 11:46 AM, HCM shares were trading at USD 282.00, down by 5.75 points or 2.00 per cent against the previous day closing price.